Targeted toxins in cancer immunotherapy

Devalingam Mahalingam; Michael J. Brumlik; Reinhard Waehler; David T. Curiel; Tyler J. Curiel

doi:10.1007/978-1-4614-4732-0_12

Targeted toxins in cancer immunotherapy

Devalingam Mahalingam, Michael J. Brumlik, Reinhard Waehler, David T. Curiel, Tyler J. Curiel

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.

Original language	English
Title of host publication	Cancer Immunotherapy
Subtitle of host publication	Paradigms, Practice and Promise
Publisher	Springer New York
Pages	377-396
Number of pages	20
ISBN (Electronic)	9781461447320
ISBN (Print)	1461447313, 9781461447313
DOIs	https://doi.org/10.1007/978-1-4614-4732-0_12
State	Published - May 1 2013

Access to Document

10.1007/978-1-4614-4732-0_12

Cite this

@inbook{b047bc31559e41ecaf9502a3183b4cb4,

title = "Targeted toxins in cancer immunotherapy",

abstract = "Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.",

author = "Devalingam Mahalingam and Brumlik, {Michael J.} and Reinhard Waehler and Curiel, {David T.} and Curiel, {Tyler J.}",

note = "Publisher Copyright: {\textcopyright} 2013 Springer Science+Business Media New York. All rights are reserved.",

year = "2013",

month = may,

day = "1",

doi = "10.1007/978-1-4614-4732-0_12",

language = "English",

isbn = "1461447313",

pages = "377--396",

booktitle = "Cancer Immunotherapy",

publisher = "Springer New York",

}

TY - CHAP

T1 - Targeted toxins in cancer immunotherapy

AU - Mahalingam, Devalingam

AU - Brumlik, Michael J.

AU - Waehler, Reinhard

AU - Curiel, David T.

AU - Curiel, Tyler J.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.

AB - Many anticancer agents are toxic to normal tissues. Thus, the potential to target treatments specifically to tumors would minimize the effects on normal tissues and afford a better safety profile compared to nontargeted treatments. Harnessing immune specificity has allowed the successful development of targeted anticancer agents. Successful targeting strategies include antibodies and derivatives, cytokines, peptides, and recombinant viruses. This chapter will summarize the current agents and strategies that exploit immune principles and reagents to develop targeting specificity to treat cancers with maximum sparing of normal tissues.

UR - http://www.scopus.com/inward/record.url?scp=84949178185&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4732-0_12

DO - 10.1007/978-1-4614-4732-0_12

M3 - Chapter

AN - SCOPUS:84949178185

SN - 1461447313

SN - 9781461447313

SP - 377

EP - 396

BT - Cancer Immunotherapy

PB - Springer New York

ER -

Targeted toxins in cancer immunotherapy

Abstract

Access to Document

Other files and links

Fingerprint

Cite this